Special Issue "Antimicrobial Resistance in Humans: The Final Frontier"

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".

Deadline for manuscript submissions: 31 March 2022.

Special Issue Editor

Dr. Matthaios Papadimitriou Olivgeris
E-Mail Website
Guest Editor
Department of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland
Interests: antimicrobial resistance; bloodstream infections; critically ill patients; carbapenemases; VRE; MRSA
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

The development of resistance after the discovery of a given antimicrobial is inevitable. The process of resistance development and its dissemination in the healthcare environment and the community are accelerated by misuse of such antimicrobials. The most important resistant bacterial pathogens are designated by the acronym “ESKAPE” that includes vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus, and multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species. During the last two decades, some Gram-negative bacteria have acquired genes that confer resistance to carbapenems, further restricting our limited armamentarium. Another problematic is the fungi resistant to antifungals, some of which, such as the Candida auris, have the capacity to provoke nosocomial epidemics.

The constant rise of antimicrobial resistance constitutes one of the most important public health issues. According to some projections, in a matter of decades, infections due to antimicrobial-resistant pathogens will be responsible for more deaths than diabetes or cancer.

Therefore, this Special Issue seeks submissions concerning the mechanisms and evolution of resistance, the epidemiology and surveillance of resistance in the clinical setting, clinical applications of existing and newer antimicrobials, and strategies to control the emergence and dissemination of resistance and improve the control of antimicrobials’ use.

Dr. Matthaios Papadimitriou Olivgeris
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial resistance
  • MRSA
  • VRE
  • carbapenemases
  • infection control
  • antifungal-resistance

Published Papers

This special issue is now open for submission.
Back to TopTop